WO2011070214A2 - Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral - Google Patents

Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral Download PDF

Info

Publication number
WO2011070214A2
WO2011070214A2 PCT/ES2010/070818 ES2010070818W WO2011070214A2 WO 2011070214 A2 WO2011070214 A2 WO 2011070214A2 ES 2010070818 W ES2010070818 W ES 2010070818W WO 2011070214 A2 WO2011070214 A2 WO 2011070214A2
Authority
WO
WIPO (PCT)
Prior art keywords
functionally equivalent
identity
fusion protein
equivalent variant
polypeptide
Prior art date
Application number
PCT/ES2010/070818
Other languages
English (en)
Spanish (es)
French (fr)
Other versions
WO2011070214A8 (es
WO2011070214A3 (es
Inventor
Pedro BERRAONDO LÓPEZ
Jessica Fioravanti
José MEDINA ECHEVERZ
Ignacio Javier Melero Bermejo
Maria Del Carmen Ochoa Nieto
Francisco De Asis Palaz0N Garcia
Silvia Bulfone-Paus
Erwin Hans Duitman
Original Assignee
Proyecto De Biomedicina Cima S.L.
Research Center Borstel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200931158A external-priority patent/ES2362062B1/es
Priority to CN201080061939.9A priority Critical patent/CN102753574B/zh
Priority to CA2783876A priority patent/CA2783876C/en
Priority to ES10814739.8T priority patent/ES2463016T3/es
Priority to JP2012542587A priority patent/JP5784626B2/ja
Priority to MX2012006691A priority patent/MX2012006691A/es
Application filed by Proyecto De Biomedicina Cima S.L., Research Center Borstel filed Critical Proyecto De Biomedicina Cima S.L.
Priority to EP10814739.8A priority patent/EP2511294B1/en
Priority to BR112012013868A priority patent/BR112012013868A8/pt
Priority to US13/514,855 priority patent/US8771664B2/en
Priority to AU2010329805A priority patent/AU2010329805B2/en
Priority to RU2012129208/10A priority patent/RU2597989C2/ru
Publication of WO2011070214A2 publication Critical patent/WO2011070214A2/es
Publication of WO2011070214A3 publication Critical patent/WO2011070214A3/es
Publication of WO2011070214A8 publication Critical patent/WO2011070214A8/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
PCT/ES2010/070818 2009-12-11 2010-12-10 Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral WO2011070214A2 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
RU2012129208/10A RU2597989C2 (ru) 2009-12-11 2010-12-10 Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения
BR112012013868A BR112012013868A8 (pt) 2009-12-11 2010-12-10 composição, proteína de fusão, polinucleotídeo, vetor ou constructo de gene, célula hospedeira , composição farmacêutica, método in vitro e uso de uma composição.
ES10814739.8T ES2463016T3 (es) 2009-12-11 2010-12-10 Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral
JP2012542587A JP5784626B2 (ja) 2009-12-11 2010-12-10 免疫療法および抗腫瘍治療のための新規な結合体および組成物
MX2012006691A MX2012006691A (es) 2009-12-11 2010-12-10 Nuevos conjugados y composiciones para inmunoterapia y tratamiento antitumoral.
CN201080061939.9A CN102753574B (zh) 2009-12-11 2010-12-10 用于免疫治疗和抗肿瘤治疗的缀合物和组合物
EP10814739.8A EP2511294B1 (en) 2009-12-11 2010-12-10 Conjugates and compositions for immunotherapy and anti-tumoral treatment
CA2783876A CA2783876C (en) 2009-12-11 2010-12-10 New conjugates and compositions for immunotherapy and antitumoral treatment
US13/514,855 US8771664B2 (en) 2009-12-11 2010-12-10 Compositions comprising apolipoprotein A polypeptide and interleukin 15, and methods of treatment using the same
AU2010329805A AU2010329805B2 (en) 2009-12-11 2010-12-10 New conjugates and compositions for immunotherapy and anti-tumoral treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES200931158A ES2362062B1 (es) 2009-12-11 2009-12-11 Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.
ESP200931158 2009-12-11
ES201030813 2010-05-27
ESP201030813 2010-05-27

Publications (3)

Publication Number Publication Date
WO2011070214A2 true WO2011070214A2 (es) 2011-06-16
WO2011070214A3 WO2011070214A3 (es) 2011-08-04
WO2011070214A8 WO2011070214A8 (es) 2011-09-29

Family

ID=43927978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2010/070818 WO2011070214A2 (es) 2009-12-11 2010-12-10 Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral

Country Status (11)

Country Link
US (1) US8771664B2 (zh)
EP (1) EP2511294B1 (zh)
JP (1) JP5784626B2 (zh)
CN (1) CN102753574B (zh)
AU (1) AU2010329805B2 (zh)
BR (1) BR112012013868A8 (zh)
CA (1) CA2783876C (zh)
ES (1) ES2463016T3 (zh)
MX (1) MX2012006691A (zh)
RU (1) RU2597989C2 (zh)
WO (1) WO2011070214A2 (zh)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US8455449B2 (en) 2011-01-18 2013-06-04 Bioniz, Llc Compositions and methods for modulating γ-c-cytokine activity
JP2016518361A (ja) * 2013-04-19 2016-06-23 シーチューヌ ファルマＣｙｔｕｎｅ Ｐｈａｒｍａ 血管漏出症候群の発生を抑制するサイトカイン治療
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
US10030059B2 (en) 2015-10-09 2018-07-24 Bioniz, Llc Modulators of gamma-C-cytokine activity
EP3727146A4 (en) * 2017-12-19 2021-10-06 Blaze Bioscience, Inc. CELL PENETRATION PEPTIDE TUMOR AND IMMUNO-ONCOLOGY ADDRESSING AGENT COMPLEXES AND METHODS OF USE
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054701A2 (en) * 2013-10-13 2015-04-16 Nova Southeastern University Analyzing immune signaling networks for identification of therapeutic targets in complex chronic medical disorders, identification of a natural killer cell population as a potential therapeutic target for gulf war illness & myalgic encephalomyelitis/chronic fatigue syndrome, and modulation of natural killer cell function by stimulation with interleukin 15
JP2017509319A (ja) 2014-01-15 2017-04-06 カドモン コーポレイション，リミティド ライアビリティ カンパニー 免疫調節剤
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
US10464982B2 (en) 2014-04-23 2019-11-05 Emory University Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto
WO2016200881A1 (en) 2015-06-10 2016-12-15 Emory University Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
CN106317225A (zh) * 2015-06-28 2017-01-11 复旦大学 具有靶向性长效白细胞介素22融合蛋白及其制备方法和用途
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
KR20190142775A (ko) 2017-04-19 2019-12-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 조작된 항원 수용체를 발현하는 면역 세포
EP3678701A4 (en) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF
WO2023064469A1 (en) * 2021-10-13 2023-04-20 Modernatx, Inc. Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
US20240043499A1 (en) * 2022-08-07 2024-02-08 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366412A2 (en) 1988-10-28 1990-05-02 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
US6828150B2 (en) 1995-03-08 2004-12-07 The Scripps Research Institute Antigen presenting system and methods for activation of T-cells
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
WO2007069090A2 (en) 2005-12-06 2007-06-21 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2009150284A2 (es) 2008-06-13 2009-12-17 Proyecto De Biomedicina Cima, S.L. Conjugados de apo-a para la administración de compuestos biológicamente activos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002061A1 (en) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Novel lipoprotein-based drug-delivery systems
CN1268641C (zh) 2000-11-10 2006-08-09 普罗蒂奥制药公司 载脂蛋白类似物
AU2008201887B2 (en) * 2000-11-10 2011-06-30 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
US8097283B2 (en) 2004-01-15 2012-01-17 Mount Sinai School Of Medicine Methods and compositions for imaging
CA2657277C (en) * 2006-07-13 2015-11-24 Upperton Limited Process for preparing particles of proteinaceous material
KR100817024B1 (ko) 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366412A2 (en) 1988-10-28 1990-05-02 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US6828150B2 (en) 1995-03-08 2004-12-07 The Scripps Research Institute Antigen presenting system and methods for activation of T-cells
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
WO2007069090A2 (en) 2005-12-06 2007-06-21 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2009150284A2 (es) 2008-06-13 2009-12-17 Proyecto De Biomedicina Cima, S.L. Conjugados de apo-a para la administración de compuestos biológicamente activos

Non-Patent Citations (50)

* Cited by examiner, † Cited by third party
Title
"Fundamental Virology", 1991, RAVEN PRESS
"Remington's Pharmaceutical Sciences", 2000, WILLIAMS & WILKINS
ALTSCHUL, S. ET AL., MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL, S. ET AL.: "BLAST Manual", NCBI NLM NIH BETHESDA
BESSARD, A. ET AL., MOL CANCER THER, vol. 8, no. 9, 2009, pages 2736 - 45
BLUM ET AL., J. CLIN. INVEST., vol. 60, 1977, pages 795 - 807
C. FAULI I TRILLO: "Tratado de Farmacia Gaienica", 1993, S.A. DE EDICIONES
CARSON, W. ET AL., J.EXP.MED., vol. 180, 1994, pages 1395 - 1403
CARTER J. ET AL., IMMUNOLOGY, vol. 57, no. 1, 1996, pages 123 - 129
CHA, E. ET AL., BREAST CANCER RES TREAT, 2009
CHOU, P.C. ET AL., VET IMMUNOL IMMUNOPATHOL, vol. 130, 2009, pages 25 - 34
DEMIRCI ET AL., CELL MOL IMMUNOL., vol. 1, 2004, pages 123 - 8
DUITMAN, E.H. ET AL., MOL CELL BIOL, vol. 28, 2008, pages 4851 - 4861
DUITMAN, E.H. ET AL., MOL CELL BIOL, vol. 28, 2008, pages 4851 - 61
EISENBERG, S. ET AL., J.LIPID RES., vol. 14, 1973, pages 446 - 458
GRABSTEIN ET AL., SCIENCE, vol. 246, 1994, pages 965 - 968
GRAVERSEN ET AL., J CARDIOVASC PHARMACOL., vol. 51, 2008, pages 170 - 177
HAZAMA, BR.J.CANCER., vol. 80, 1999, pages 1420 - 1426
HODGES ET AL., EXP.OPIN.BIOI.THER, vol. 3, 2003, pages 91 - 918
KLEBANOFF, PROC.NATL.ACAD.SCI.USA 2004, vol. 101, 2004, pages 1969 - 1974
LERCH ET AL., VOX SANG, vol. 71, 1996, pages 155 - 164
LIN, C.Y. ET AL., CANCER LETT, vol. 272, no. 2, 2008, pages 285 - 95
LINDGREN, A. ET AL., TRENDS PHARMACOL. SCI, vol. 21, 2000, pages 99 - 103
LIU ET AL., SCIENCE, vol. 305, 1999, pages 1437 - 1441
LIU, F. ET AL., GENE THER, vol. 6, 1999, pages 1258 - 66
LODOLCE ET AL., IMMUNITY, vol. 9, 1998, pages 669 - 676
LODOLCE ET AL.: "IL15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation", IMMUNITY, vol. 9, 1998, pages 669 - 676
LUNDBERG, M ET AL., MOL. THERAPY, vol. 8, 2003, pages 143 - 150
MEAZZA ET AL., EUR. J. IMMUNOL., vol. 27, 1997, pages 1049 - 1054
MEAZZA ET AL.: "Expression of two interleukin-15 mRNA isoforms in human tumors does not correlate with secretion: role of different signal peptides", EUR J IMMUNOL, vol. 27, 1997, pages 1049 - 1054
MEAZZA, INT.J.CANCER, vol. 87, 2000, pages 574 - 581
MONACO ET AL., EMBO J., vol. 6, 1987, pages 3253 - 3260
MONTES ET AL., CLIN. EXP. IMMUNOL., vol. 142, 2005, pages 292 - 302
MORTIER ET AL., J.BIOI.CHEM., vol. 281, 2006, pages 1612 - 1619
MORTIER, E. ET AL., J BIOL CHEM, vol. 281, no. 3, 2006, pages 1612 - 9
MULLER, K.M. ET AL., METHODS. ENZIMOLOGY, vol. 328, 2000, pages 261 - 281
NEEDLEMAN; WUNSCH, J. MOL.. BIOL., vol. 48, 1970, pages 443
NIELSEN, B.B. ET AL., FEBS LETT., vol. 412, 1997, pages 388 - 396
PACK P.; PLUCKTHUN, A., BIOCHEMISTRY, vol. 31, 1992, pages 1579 - 1584
PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. (U.S.A.), vol. 85, 1988, pages 2444
RUBINSTEIN M.P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 9166 - 71
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2001, LABORATORY PRESS, COLD SPRING HARBOR
SCHWARZE, S.R. ET AL., TRENDS PHARMACOL. SCI., vol. 21, 2000, pages 45 - 48
SMITH; WATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482
SNYDER, E.L.; DOWDY, S.F., PHARM. RES., vol. 21, 2004, pages 389 - 393
STOKLASEK T.A. ET AL., J. IMMUNOL., vol. 177, 2006, pages 6072 - 80
SUZUKI, J.LEUOKOC.BIOL., vol. 69, 2001, pages 531 - 537
TEMPLETON, DNA CELL BIOL., vol. 21, 2002, pages 857 - 867
TRANSPLANTATION, vol. 67, 1999, pages 605 - 613
ZHANG, M. ET AL., PROC NATL ACAD SCI USA, vol. 106, 2009, pages 7513 - 8

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675672B2 (en) 2011-01-18 2017-06-13 Bioniz, Llc Compositions and methods for modulating gamma-C-cytokine activity
US11834519B2 (en) 2011-01-18 2023-12-05 Bioniz Therapeutics, Inc. Compositions and methods for modulating γ-c-cytokine activity
US8455449B2 (en) 2011-01-18 2013-06-04 Bioniz, Llc Compositions and methods for modulating γ-c-cytokine activity
US11708392B2 (en) 2011-01-18 2023-07-25 Bioniz, Llc Peptide conjugates
US10808009B2 (en) 2011-01-18 2020-10-20 Bioniz, Llc Peptide conjugates
US10227382B2 (en) 2011-01-18 2019-03-12 Bioniz, Llc Method of designing a peptide and/or peptide derivative for modulating gamma-c-cytokine activity
US9133244B2 (en) 2011-01-18 2015-09-15 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
US9133243B2 (en) 2011-01-18 2015-09-15 Bioniz, Llc Compositions and methods for modulating γ-c-cytokine activity
US9951105B2 (en) 2011-01-18 2018-04-24 Bioniz, Llc Methods of developing selective peptide antagonists
EP3406723A1 (en) * 2011-06-24 2018-11-28 Cytune An il-15 and il-15ralpha sushi domain based immunocytokines
WO2012175222A1 (en) * 2011-06-24 2012-12-27 Cytune AN IL-15 AND IL-15Rα SUSHI DOMAIN BASED IMMUNOCYTOKINES
US11753454B2 (en) 2011-06-24 2023-09-12 Cytune Pharma IL-15 and IL-15R\alpha sushi domain based immunocytokines
KR20140062030A (ko) * 2011-06-24 2014-05-22 싸이튠 IL-15 및 IL-15Rα 스시 도메인에 기초한 면역시토킨
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
CN104093841A (zh) * 2011-06-24 2014-10-08 西图恩医药Sas 基于IL-15和IL-15Rα SUSHI结构域的免疫细胞因子
KR101977312B1 (ko) 2011-06-24 2019-05-13 싸이튠 파마 IL-15 및 IL-15Rα 스시 도메인에 기초한 면역시토킨
US10626155B2 (en) 2011-06-24 2020-04-21 Cytune Pharma IL-15 and IL-15R\alpha sushi domain based immunocytokines
JP2014524737A (ja) * 2011-06-24 2014-09-25 サイチューン ＩＬ−１５およびＩＬ−１５ＲαＳＵＳＨＩドメインに基づいた免疫サイトカイン
US10899816B2 (en) 2011-06-24 2021-01-26 Inserm (Institut National De La Santé Et De La Recherche Medicale) IL-15 and IL-15Rα sushi domain based immunocytokines
JP2021073260A (ja) * 2013-04-19 2021-05-13 シーチューヌ ファルマＣｙｔｕｎｅ Ｐｈａｒｍａ 血管漏出症候群の発生を抑制するサイトカイン治療
JP2019108332A (ja) * 2013-04-19 2019-07-04 シーチューヌ ファルマＣｙｔｕｎｅ Ｐｈａｒｍａ 血管漏出症候群の発生を抑制するサイトカイン治療
JP2016518361A (ja) * 2013-04-19 2016-06-23 シーチューヌ ファルマＣｙｔｕｎｅ Ｐｈａｒｍａ 血管漏出症候群の発生を抑制するサイトカイン治療
US10854312B2 (en) 2013-12-10 2020-12-01 Bioniz, Llc Selective peptide antagonists
US11462297B2 (en) 2013-12-10 2022-10-04 Bioniz, Llc Selective peptide antagonists
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
US11400134B2 (en) 2015-10-09 2022-08-02 Bioniz, Llc Modulating gamma-c-cytokine activity
US10030058B2 (en) 2015-10-09 2018-07-24 Bioniz, Llc Modulating gamma-C-cytokine activity
US10030059B2 (en) 2015-10-09 2018-07-24 Bioniz, Llc Modulators of gamma-C-cytokine activity
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3727146A4 (en) * 2017-12-19 2021-10-06 Blaze Bioscience, Inc. CELL PENETRATION PEPTIDE TUMOR AND IMMUNO-ONCOLOGY ADDRESSING AGENT COMPLEXES AND METHODS OF USE
US11866466B2 (en) 2017-12-19 2024-01-09 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof

Also Published As

Publication number Publication date
RU2597989C2 (ru) 2016-09-20
JP2013513377A (ja) 2013-04-22
CN102753574B (zh) 2015-05-20
CA2783876A1 (en) 2011-06-16
CA2783876C (en) 2018-04-03
MX2012006691A (es) 2013-02-26
BR112012013868A8 (pt) 2017-12-26
EP2511294B1 (en) 2014-02-26
WO2011070214A8 (es) 2011-09-29
RU2012129208A (ru) 2014-01-20
CN102753574A (zh) 2012-10-24
JP5784626B2 (ja) 2015-09-24
ES2463016T3 (es) 2014-05-27
WO2011070214A3 (es) 2011-08-04
US20120244118A1 (en) 2012-09-27
AU2010329805B2 (en) 2016-07-14
AU2010329805A1 (en) 2012-07-05
EP2511294A2 (en) 2012-10-17
US8771664B2 (en) 2014-07-08
BR112012013868A2 (pt) 2017-01-10

Similar Documents

Publication Publication Date Title
ES2463016T3 (es) Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral
EP3307783B1 (en) Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
ES2315008T3 (es) Composiciones que contienen un agente de union a receptor ox-40 o un acido nucleido que codifica el mismo y procedimientos para potenciar la respuesta inmune especifica de antigeno.
ES2518393T3 (es) Moléculas de fusión y variantes de IL-15
Nelms et al. The IL-4 receptor: signaling mechanisms and biologic functions
ES2498190T3 (es) Receptores de linfocitos T
ES2268863T3 (es) Receptores quimericos.
JP7250790B2 (ja) Ｉｌ－２ムテインおよびその使用
US20150079025A1 (en) T cell receptor fusions and conjugates and methods of use thereof
WO2012127464A2 (en) Constitutively activated t cells for use in adoptive cell therapy
WO2009150284A2 (es) Conjugados de apo-a para la administración de compuestos biológicamente activos
CA2268752A1 (en) Plasmids encoding immunogenic proteins and intracellular as follows
KR20160016725A (ko) 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포
MX2010012746A (es) Molecula adaptadora para la administracion de vectores de adenovirus.
ES2413631T3 (es) Uso de formas solubles de CD83 y ácidos nucleicos que las codifican para el tratamiento o prevención de enfermedades
WO2018162450A1 (en) New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
TW202115105A (zh) Ｉｌ２激動劑
EP2374813A1 (en) Use of phenol-soluble modulins for vaccine development
ES2362062A1 (es) Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.
US20210008167A1 (en) T cell receptor fusions and conjugates and methods of use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080061939.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10814739

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2783876

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012542587

Country of ref document: JP

Ref document number: 13514855

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/006691

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010329805

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 5498/DELNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2010329805

Country of ref document: AU

Date of ref document: 20101210

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010814739

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012129208

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012013868

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012013868

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120608